Anastrozole Chemical Structure (Anastrozole Chemical Structure)
Anastrozole
Product Images NDC 67877-171
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 67877-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Ascend Anastrozole Tablets (1 mg product label)
This is a medication containing 1mg of anastrozole USP. The usual dosage is stated to be included in a separate accompanying document, and a warning is given to keep it out of reach of children. The tablets should be stored at a controlled room temperature of 20-25°C (68-77°F). The manufacturer is Natco Pharma Limited based in Kothur, India, and the product is distributed by Ascend Laboratories, LLC based in Montvale, NJ. Some additional characters are present that do not form coherent text.*
Figure 1 (Figure 1)
This is a Kaplan Meier survival curve for patients who were randomized to receive either Anastrozole tablets or Tamoxifen monotherapy in the ATAC trial. The x-axis plots the disease-free survival in months, while the y-axis shows the proportion of patients who remain disease-free. The numbers on the top of the graph represent the number of patients still at risk of developing the disease at each time point.*
Figure 2 (Figure 2)
This is a figure showing the disease-free survival for a subpopulation of patients with hormone receptor-positive cancer who were randomized to receive either Anastrozole or Tamoxifen monotherapy in the ATAC trial. The graph displays the proportion of patients who remained alive and disease-free over time, represented in months, with the numbers of patients at risk for each treatment option at different times.*
Figure 3 (Figure 3)
The image is a graph (specifically a Kaplan-Meier probability graph) displaying the likelihood of disease progression over time (in months) for patients who participated in Trial 0030 and were randomized to receive either anastrozole or tamoxifen as treatment. The x-axis displays the time to progression, and the y-axis shows the probability of progression. The graph shows that patients who received anastrozole had a lower probability of disease progression compared to those who received tamoxifen.*
Figure 4 (Figure 4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
